WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1891-01-01

Employees: 10K

Market Cap: -

Website: http://www.medschool.wustl.edu

Clinical Trials

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Metastatic Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Olaparib
Drug: Pembrolizumab
Drug: Carboplatin
Procedure: Peripheral blood draw

First Posted Date: 2020-11-25

Last Posted Date: 2024-07-19

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 30

Registration Number: NCT04643379

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Wellness Through Mobile Health

Not Applicable

Completed

Conditions: Chronic Pain
Anxiety Disorders
Depression
Musculoskeletal Diseases

Interventions: Behavioral: Smartphone app (Wysa)

First Posted Date: 2020-11-23

Last Posted Date: 2021-12-01

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 60

Registration Number: NCT04640090

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Psychosocial Syndemics of Heart Failure

Active, not recruiting

Conditions: Heart Failure

Interventions: Other: Hospitalization

First Posted Date: 2020-11-20

Last Posted Date: 2024-10-28

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 367

Registration Number: NCT04637776

Locations: 🇺🇸
Barnes-Jewish Hospital at Washington University Medical Center, Saint Louis, Missouri, United States

Leveraging Social Media to Identify and Connect Teens With Eating Disorders to a Mobile Guided Self-Help Mobile Intervention

Phase 1

Completed

Conditions: Eating Disorders

Interventions: Device: Space From Body and Eating Concerns- Teen

First Posted Date: 2020-11-19

Last Posted Date: 2024-10-28

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 161

Registration Number: NCT04636840

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Sleep Trial to Prevent Alzheimer's Disease

Phase 2

Recruiting

Conditions: Sleep
Alzheimer Disease

Interventions: Drug: Suvorexant 20 mg
Drug: Placebo

First Posted Date: 2020-11-16

Last Posted Date: 2024-11-27

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 200

Registration Number: NCT04629547

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Phase 1

Terminated

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Tazemetostat
Drug: Pembrolizumab

First Posted Date: 2020-11-10

Last Posted Date: 2024-02-21

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 13

Registration Number: NCT04624113

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.

Phase 2

Completed

Conditions: Alzheimers Disease, Familial
Dementia
Alzheimers Disease

Interventions: Drug: Matching Placebo (Gantenerumab)
Drug: Matching Placebo (Solanezumab)
Drug: Solanezumab
Drug: Gantenerumab

First Posted Date: 2020-11-10

Last Posted Date: 2022-09-22

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 194

Registration Number: NCT04623242

Locations: 🇺🇸
University of California San Diego Medical Center, La Jolla, California, United States
🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States
🇺🇸
Columbia University, New York, New York, United States

and more 22 locations

Using Health Information Technology to Improve Health Behaviors and Promote Cardiovascular Health Among Adolescent and Young Adult Cancer Survivors

Not Applicable

Completed

Conditions: Cardiovascular Disease
Young Adult Cancer Survivors

Interventions: Behavioral: Wait-List Control
Behavioral: PREVENT tool

First Posted Date: 2020-11-10

Last Posted Date: 2022-08-25

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 26

Registration Number: NCT04623190

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Serum Neurofilament Light (NfL) as a Marker for Brain Injury in Individuals Undergoing Chimeric Antigen Receptor-modified T Therapy

Terminated

Conditions: Neurotoxicity

First Posted Date: 2020-11-04

Last Posted Date: 2023-09-21

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 17

Registration Number: NCT04614987

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)

Phase 2

Active, not recruiting

Conditions: RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy

Interventions: Drug: Crizanlizumab

First Posted Date: 2020-11-02

Last Posted Date: 2023-02-14

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 20

Registration Number: NCT04611880

Locations: 🇺🇸
Andria Ford, Saint Louis, Missouri, United States
🇺🇸
Perelman School of Medicine; University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy